NKTR vs SNY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NKTR and SNY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NKTR and SNY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Nektar Therapeutics is a San Francisco based, Nasdaq-listed clinical-stage biopharmaceutical company whose pipeline is anchored by rezpegaldesleukin (rezpeg), a first-in-class biologic designed to stimulate and expand regulatory T cells to restore immune balance. Nektar regained full rights to the molecule from Eli Lilly and is developing it across immuno-dermatology indications, with a Phase 2b program in moderate-to-severe atopic dermatitis (REZOLVE-AD, 393 patients), a Phase 2b program in severe-to-very-severe alopecia areata (REZOLVE-AA), and a Phase 2 study in type 1 diabetes. In February 2026 the company reported maintenance data from REZOLVE-AD showing durable and new responses on key disease measures with both monthly and quarterly dosing, and rezpeg holds FDA Fast Track designation in atopic dermatitis.

Full NKTR guide

Sanofi S.A. is one of the world's largest pharmaceutical companies, based in France and organized around biopharma (specialty care, general medicines) and vaccines. Its single most important product is Dupixent, an immunology drug co-developed with Regeneron that treats conditions like eczema, asthma, and COPD; Dupixent sales moved above the roughly four-billion-euro-per-quarter mark in Q1 2026 and grew more than 30% year over year, making it the engine of the company's revenue growth. Sanofi also runs a major vaccines business (including the RSV antibody Beyfortus and the newly acquired hepatitis-B vaccine Heplisav-B) and spun off its consumer-health arm, Opella (Allegra, Icy Hot, Dulcolax), in 2025 to focus purely on innovative medicines and vaccines.

Full SNY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NKTR drivers: Rezpegaldesleukin in atopic dermatitis; Alopecia areata expansion.
• SNY drivers: Dupixent as the growth engine; Pipeline and new launches.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. For SNY, the clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NKTR if you believe its drivers more; SNY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NKTR and SNY guides.

NKTR. As a clinical-stage biopharma, Nektar carries no meaningful earnings, so traditional profit multiples do not apply and its value reflects the perceived probability and size of rezpegaldesleukin's opportunity. The ~$1B cash position is a large fraction of the ~$2.5B market cap, meaning much of the equity value is tied to pipeline expectations rather than current operations.

SNY. Figures are approximate, drawn from public 2026 reporting, and tied to the asOf date; verify live numbers before acting. Sanofi reports in euros, so the dollar value of SNY and its dividend also depends on the euro-to-dollar exchange rate. As a defensive large-cap pharma, the stock tends to trade on pipeline news, Dupixent momentum, and the eventual patent-expiry timeline rather than on sharp cyclical swings.

Headline figures (approximate, July 2026): NKTR shows share price ~$74 (early July 2026), market cap ~$2.5B, q1 2026 revenue ~$10.9M, q1 2026 net loss ~$44.9M (~$1.82/share); SNY shows company type Large-cap, diversified global pharmaceutical company (French, US-listed as an ADR on Nasdaq), market cap ~$107 billion (approximate; among the larger global pharma names), q1 2026 revenue ~10.5 billion euros, ahead of consensus (reported figures are in euros), q1 2026 business eps ~1.88 euros, up ~14% at constant exchange rates.

NKTR and SNY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NKTR and SNY exposure against your real portfolio. It is not an investment adviser.